Similar articles

• Clinical challenges in chronic lymphocytic leukemia.

  O'Brien S. O'Brien S. Semin Hematol. 1998 Jul;35(3 Suppl 3):22-6. Semin Hematol. 1998. PMID: 9685176 Review. No abstract available.
• A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia.

  Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. Strati P, et al. Leuk Lymphoma. 2015 Jun;56(6):1878-80. doi: 10.3109/10428194.2014.974049. Epub 2014 Nov 20. Leuk Lymphoma. 2015. PMID: 25311497 Free PMC article. Clinical Trial. No abstract available.
• Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.

  Waselenko JK, Grever MR, Beer M, Lucas MA, Byrd JC. Waselenko JK, et al. Semin Oncol. 2000 Apr;27(2 Suppl 5):44-51. Semin Oncol. 2000. PMID: 10877052 Review.
• Treating chronic lymphocytic leukemia with a combination of rituximab and alemtuzumab: a "successful couple," but are they still relevant together?

  Geisler CH, Tadmor T, Polliack A. Geisler CH, et al. Leuk Lymphoma. 2015 Feb;56(2):275-6. doi: 10.3109/10428194.2014.946026. Epub 2014 Aug 20. Leuk Lymphoma. 2015. PMID: 25065699 No abstract available.
• Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.

  Lin TS, Flinn IW, Lucas MS, Porcu P, Sickler J, Moran ME, Lucas DM, Heerema NA, Grever MR, Byrd JC. Lin TS, et al. Leukemia. 2005 Jul;19(7):1207-10. doi: 10.1038/sj.leu.2403782. Leukemia. 2005. PMID: 15858611 Clinical Trial.